Knowldge

Knowledge

variant

Variant-specific neutralising antibodies levels induced by the PHH-1 V SARS-CoV-2 vaccine (Bimervax®) by HIPRA

Envasadora Dosificadora

Safety and immunogenicity of a PHH-1V booster dose after different prime vaccination schemes against COVID-19: Phase III clinical trial final results up to one year

human health laboratory

Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results

laboratory vaccines

Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months

HIPRA R&D Projects

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

HIPRA R&D Projects

Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2

HIPRA R&D Projects

Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate

HIPRA laboratory R&D

Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates

About RBDCOV Talks

RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine?